



**PHARMACY AND THERAPEUTICS COMMITTEE  
MEDICAID MEETING MINUTES  
November 7, 2024**

*Attendance:* Microsoft Teams Meeting  
 Gary Bledsoe, Staff/Clinical Pharmacist; Dr. Kevin Caputo, Magellan Health; Edgar Chou, Jefferson Health; Dr. Neal Demp, Community Behavior Health; Danielle Dolores, Director of Pharmacy; George E. Downs, Dean Emeritus and Professor, St. Joseph's University; Leah Finken, Clinical Programs Pharmacist; Sharon Ford, Staff/Clinical Pharmacist; Paul Goebel, Assistant Director Pharmacy, Jefferson; Merleen Harris-Williams, Medical Director; Yelena Hedrick, Staff/Clinical Pharmacist; Gia Ho, Pharmacy Student Intern; Samantha Jackson, Clinical Pharmacist; Ruth John, Pharmacy Resident; Lawrence Jones, Retired Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Brandi Mahler, Supervisor Pharmacy Technicians; Hannah McCaffrey, Manager Pharmacy Regulations & Implementation; Lisa Murray, Staff/Clinical Pharmacist; Kateryna Olchowecky, Clinical Programs Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Sydney Rosenthal, Pharmacy Student Intern; Sara Sadiq, Staff/Clinical Pharmacist; Julie Samuel, Clinical Programs Pharmacist; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Sajida Sikunder, Pharmacy Student Intern; Mike Smikovecus, Staff/Clinical Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist; Justin Steffan, Pharmacy Resident; Brian Swift, Enterprise Vice President/Chief Pharmacy Officer, Jefferson Health; Jessica Tran, Staff/Clinical Pharmacist; Fallan Vaisberg, Formulary Pharmacist; Ramesh Vangala, Vice President of Pharmacy Operations; Jeanine Zubrzycki, Staff/Clinical Pharmacist

*Excused:* Justin Bittner, Medical Director; Connie Chan, Staff/Clinical Pharmacist; Jerry Crawford, Staff/Clinical Pharmacist; Demian Elder, Medical Director; Oluwatoyin Fadeyibi, Community Behavior Health; Sanjiv Raj, Associate VP Customer Engagement; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health

*Minutes taken by:* Joana Iverson

**I. Administrative Update**

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<b>Minutes Review/Approval</b>	D. Dolores presented the minutes from the August 2024 meeting to the Committee for review.	The Committee approved the minutes from our last meeting as presented.	D. Dolores	Resolved
<b>Administrative Update</b>	Annual review of Policies & Procedures <ul style="list-style-type: none"> <li>• Pharmacy Prior Authorization</li> <li>• Pharmacy Operations and Responsibilities</li> <li>• Pharmacy Formulary Management</li> <li>• Immediate Need 5 Day and 15 Day</li> </ul>		D. Dolores	Informational

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
	<ul style="list-style-type: none"> <li>• Pharmacy Vendor Management</li> <li>• Drug Utilization Review</li> <li>• Recipient Restriction Program</li> </ul>			

## II. Drug Formulary Review/Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<b>2024 Prior Authorization Criteria Review (non-PDL)</b>	<p>The Committee reviewed and approved as presented.</p> <ul style="list-style-type: none"> <li>• Apomorphine</li> <li>• Bexarotene Gel</li> <li>• Camzyos</li> <li>• Corticotropin Injection Gel</li> <li>• Evryssi</li> <li>• Imcivree</li> <li>• Linezolid</li> <li>• Megace ES</li> <li>• Rezdiffra</li> <li>• Sivextro</li> <li>• Strensiq</li> <li>• Tavneos</li> <li>• Vijoice</li> <li>• Voxzogo</li> <li>• Winrevair</li> </ul>	The Committee approved as presented.	F. Vaisberg Y. Hedrick R. John J. Steffan	Resolved
<b>2024 Quantity Limit Additions</b>	<p>The Committee reviewed the 2024 Quantity Limit Additions. The Committee approved as presented.</p> <ul style="list-style-type: none"> <li>• Abilify Asimtufii 720 mg/2.4 mL prefilled syringe - 0.05 mL/day</li> <li>• Abilify Asimtufii 960 mg/3.2 mL prefilled syringe - 0.06 mL/day</li> <li>• Camzyos 10 mg capsule - 1/day</li> <li>• Camzyos 15 mg capsule - 1/day</li> <li>• Camzyos 2.5 mg capsule - 1/day</li> <li>• Camzyos 5 mg capsule - 1/day</li> <li>• Cobenfy 100-20 mg capsule - 2/day</li> <li>• Cobenfy 125-30 mg capsule - 2/day</li> <li>• Cobenfy 50-20 mg capsule - 2/day</li> <li>• Doxylamine Succinate-Pyridoxine DR Tablet - 4/day</li> <li>• Lybalvi 10-10 mg tablet - 1/day</li> <li>• Lybalvi 15-10 mg tablet - 1/day</li> <li>• Lybalvi 20-10 mg tablet - 1/day</li> <li>• Lybalvi 5-10 mg tablet - 1/day</li> <li>• Miebo - 0.1/day</li> </ul>	The Committee approved as presented. The 2024 Quantity Limit Additions will be sent to PARP for approval.	F. Vaisberg	Resolved

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
	<ul style="list-style-type: none"> <li>• Otezla 20 mg tablet - 2 tablets/day</li> <li>• Retevmo 120 mg tablet - 2 tablets/day</li> <li>• Retevmo 160 mg tablet - 2 tablets/day</li> <li>• Retevmo 40 mg tablet - 3 tablets/day</li> <li>• Retevmo 80 mg tablet - 2 tablets/day</li> <li>• Rezdifra 100 mg tablet - 1/day</li> <li>• Rezdifra 60 mg tablet - 1/day</li> <li>• Rezdifra 80 mg tablet - 1/day</li> <li>• Simlandi 1-pen kit 40mg/0.4mL - 0.22/day</li> <li>• Simlandi 2-pen kit 40mg/0.4mL - 0.22/day</li> <li>• Taltz 20 mg/0.25mL soln pre-filled syringe - 0.01/day</li> <li>• Taltz 40 mg/0.5mL soln pre-filled syringe - 0.02/day</li> <li>• Taltz 80 mg/mL soln autoinjector - 0.15/day</li> <li>• Taltz 80 mg/mL soln pre-filled syringe - 0.15/day</li> <li>• Tavneos 10 mg capsule - 6/day</li> <li>• Victoza 18 mg/3mL pen - 0.5/day</li> <li>• Zavzpret 10 mg nasal spray - 0.27/day</li> <li>• Zepbound 2.5 mg/0.5mL solution - 0.072 mL/day Medicaid; Excluded CHIP</li> <li>• Zepbound 5 mg/0.5mL solution - 0.072 mL/day Medicaid; Excluded CHIP</li> <li>• Zoryve 0.3% foam - 2 g/day</li> </ul>			
<b>2024 Quantity Limit Removals</b>	<p>The Committee reviewed the 2024 Quantity Limit Removals. The Committee approved as presented.</p> <ul style="list-style-type: none"> <li>• Diastat Pediatric 2.5 mg gel</li> <li>• Diazepam 2.5 mg gel</li> <li>• Diastat AcuDial 10 mg gel</li> <li>• Diazepam 10 mg gel</li> <li>• Diastat AcuDial 20 mg gel</li> <li>• Diazepam 20 mg gel</li> </ul>	<p>The Committee approved as presented. The 2024 Quantity Limit Removals will be sent to PARP for approval.</p>	<p>F. Vaisberg</p>	<p>Resolved</p>
<b>2025 DHS Prior Authorization Criteria Review (effective 1/6/2025)</b>	<p>The Committee reviewed the 2025 DHS Prior Authorization Criteria. The Committee approved as presented.</p> <ul style="list-style-type: none"> <li>• Analgesics, Non-Opioid Barbiturate Combinations</li> <li>• Analgesics, Opioid Long-Acting</li> <li>• Analgesics, Opioid Short-Acting</li> <li>• Anticonvulsants</li> <li>• Antidepressants, Other</li> <li>• Antidepressants, SSRIs</li> <li>• Antifibrotic Respiratory Agents</li> <li>• Antiparkinson's Agents</li> </ul>	<p>The Committee approved as presented.</p>	<p>F. Vaisberg</p>	<p>Resolved</p>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING												
	<ul style="list-style-type: none"> <li>• <i>Antipsychotics</i></li> <li>• <i>Botulinum Toxins</i></li> <li>• <i>Colony Stimulating Factors</i></li> <li>• <i>Cytokine and CAM Antagonists</i></li> <li>• <i>Hepatic and Biliary Agents (formerly Bile Salts)</i></li> <li>• <i>Hereditary Angioedema (HAE) Agents</i></li> <li>• <i>Immunomodulators, Atopic Dermatitis</i></li> <li>• <i>Lipotropics, Other</i></li> <li>• <i>Migraine Acute Treatment Agents</i></li> <li>• <i>Migraine Prevention Agents</i></li> <li>• <i>Monoclonal Antibodies – Anti-IL, Anti-IgE</i></li> <li>• <i>Multiple Sclerosis Agents</i></li> <li>• <i>Natalizumab</i></li> <li>• <i>Neuropathic Pain Agents</i></li> <li>• <i>Oncology Agents, Oral</i></li> <li>• <i>Pancreatic Enzymes</i></li> <li>• <i>Phosphate Lowering Agents (previously Phosphate Binders)</i></li> <li>• <i>Pulmonary Arterial Hypertension (PAH) Agents, Oral and Inhaled</i></li> <li>• <i>Skeletal Muscle Relaxants</i></li> <li>• <i>Stimulants and Related Agents</i></li> <li>• <i>Thalidomide and Derivatives</i></li> <li>• <i>Thrombopoietics</i></li> <li>• <i>Ulcerative Colitis Agents</i></li> </ul>															
<b>Drugs moving to NPD Status (NPD drugs require PA)</b>	<i>The Committee reviewed the Drugs moving to NPD Status. The Committee approved as presented.</i>	<i>The Committee approved as presented. The Drugs moving to NPD Status will be sent to PARP for approval.</i>	<i>F. Vaisberg</i>	<i>Resolved</i>												
	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 30%;"><i>Drug Name</i></th> <th><i>Alternative(s)</i></th> </tr> </thead> <tbody> <tr> <td data-bbox="357 1045 667 1170"><i>Zyprexa Relprevv</i></td> <td data-bbox="667 1045 1167 1170"><i>Abilify Asimtufii/Maintena, Aristada ER/Initio, Invega Hafyera/Sustenna/Trinza, Perseris ER, Risperdal Consta, Rykindo, Uzedy ER</i></td> </tr> <tr> <td data-bbox="357 1170 667 1232"><i>Nyvepria (pegfilgrastim-apgf)</i></td> <td data-bbox="667 1170 1167 1232"><i>Fulphila, Granix, Neupogen, Releuko</i></td> </tr> <tr> <td data-bbox="357 1232 667 1265"><i>Actemra</i></td> <td data-bbox="667 1232 1167 1265"><i>Tyenne</i></td> </tr> <tr> <td data-bbox="357 1265 667 1359"><i>Amjevita 50mg</i></td> <td data-bbox="667 1265 1167 1359"><i>Adalimumab-acf/adaz/adbm (BI labeler only)/fkpj, Amjevita 100mg/mL, Hadlima, Humira, Simlandi, Yusimry</i></td> </tr> <tr> <td data-bbox="357 1359 667 1386"><i>Cimetidine Solution</i></td> <td data-bbox="667 1359 1167 1386"><i>Famotidine Suspension</i></td> </tr> </tbody> </table>				<i>Drug Name</i>	<i>Alternative(s)</i>	<i>Zyprexa Relprevv</i>	<i>Abilify Asimtufii/Maintena, Aristada ER/Initio, Invega Hafyera/Sustenna/Trinza, Perseris ER, Risperdal Consta, Rykindo, Uzedy ER</i>	<i>Nyvepria (pegfilgrastim-apgf)</i>	<i>Fulphila, Granix, Neupogen, Releuko</i>	<i>Actemra</i>	<i>Tyenne</i>	<i>Amjevita 50mg</i>	<i>Adalimumab-acf/adaz/adbm (BI labeler only)/fkpj, Amjevita 100mg/mL, Hadlima, Humira, Simlandi, Yusimry</i>	<i>Cimetidine Solution</i>	<i>Famotidine Suspension</i>
	<i>Drug Name</i>				<i>Alternative(s)</i>											
	<i>Zyprexa Relprevv</i>				<i>Abilify Asimtufii/Maintena, Aristada ER/Initio, Invega Hafyera/Sustenna/Trinza, Perseris ER, Risperdal Consta, Rykindo, Uzedy ER</i>											
	<i>Nyvepria (pegfilgrastim-apgf)</i>				<i>Fulphila, Granix, Neupogen, Releuko</i>											
	<i>Actemra</i>				<i>Tyenne</i>											
<i>Amjevita 50mg</i>	<i>Adalimumab-acf/adaz/adbm (BI labeler only)/fkpj, Amjevita 100mg/mL, Hadlima, Humira, Simlandi, Yusimry</i>															
<i>Cimetidine Solution</i>	<i>Famotidine Suspension</i>															

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<b>Drugs moving to PRD Status</b>	<p>The Committee reviewed the Drugs moving to PRD Status. The Committee approved as presented.</p> <ul style="list-style-type: none"> <li>• Adalimumab-aac<sup>PA</sup></li> <li>• Adalimumab-adaz(CF) Pen/Syringe<sup>PA</sup></li> <li>• Adalimumab-adbm(CF) Pen (BI only)<sup>PA</sup></li> <li>• Adapalene-Benzoyl Peroxide 0.3%-2.5% Gel Pump</li> <li>• Ajoyv Autoinjector<sup>PA</sup></li> <li>• Ajoyv Syringe<sup>PA</sup></li> <li>• Akeega Tablet<sup>PA</sup></li> <li>• Altuviiiio<sup>PA</sup></li> <li>• Antibiotic Plus (neomycin-polymyxin B-pramoxine) Cream</li> <li>• Augtyro Capsule<sup>PA</sup></li> <li>• Bosulif Capsule<sup>PA</sup></li> <li>• Briumvi (ublituximab-xiiy) Vial<sup>PA</sup></li> <li>• Cibinqo Tablet</li> <li>• Contour Plus (50-count and 100-count)</li> <li>• Contour Plus Blue</li> <li>• Doxylamine Succinate-Pyridoxine DR Tablet</li> <li>• Eletriptan Tablet</li> <li>• Epidiolex (cannabidiol extract) Solution</li> <li>• Eysuvis Drops<sup>PA</sup></li> <li>• Fruzaqla Capsule<sup>PA</sup></li> <li>• Glucagon Emergency Kit</li> <li>• Ingrezza Sprinkle Capsule<sup>PA</sup></li> <li>• Iwilfin Tablet<sup>PA</sup></li> <li>• Memantine ER Capsule</li> <li>• Nucala 100 mg/ml Syringe<sup>PA</sup></li> <li>• Nucala 100 mg/ml Vial<sup>PA</sup></li> <li>• Ogsiveo Tablet<sup>PA</sup></li> <li>• Ojemda Suspension<sup>PA</sup></li> <li>• Ojemda Tablet<sup>PA</sup></li> <li>• Ojjaara Tablet<sup>PA</sup></li> <li>• Posaconazole DR Tablet</li> <li>• Rozlytrek Pellet Packet<sup>PA</sup></li> <li>• Rykindo (risperidone) Vial</li> <li>• S kyrizi On-Body Injector<sup>PA</sup></li> <li>• S kyrizi Pen<sup>PA</sup></li> <li>• S kyrizi Syringe<sup>PA</sup></li> <li>• S kyrizi Vial<sup>PA</sup></li> <li>• S kytrofa Cartridge<sup>PA</sup></li> </ul>	<p>The Committee approved as presented. The Drugs moving to PRD Status will be sent to PARP for approval.</p>	<p>F. Vaisberg</p>	<p>Resolved</p>


TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
	<ul style="list-style-type: none"> <li>• Tezspire Syringe<sup>PA</sup></li> <li>• Torpenz Tablet<sup>PA</sup></li> <li>• Truqap Tablet<sup>PA</sup></li> <li>• Tyenne Autoinjector<sup>PA</sup></li> <li>• Tyenne Syringe<sup>PA</sup></li> <li>• Tyenne Vial<sup>PA</sup></li> <li>• Ubrelvy Tablet<sup>PA</sup></li> <li>• Uzedy ER</li> <li>• Xalkori Pellet<sup>PA</sup></li> <li>• Xiidra Dropperette</li> <li>• Yargesa Capsule<sup>PA</sup></li> </ul>			
<p><b>Quantity Limit Additions (effective 1/6/2025)</b></p>	<p>The Committee reviewed the Quantity Limit Additions. The Committee approved as presented.</p> <ul style="list-style-type: none"> <li>• Adalimumab-aacf (2 pen) 40 mg/0.8mL Pen - 0.11/day</li> <li>• Adalimumab-aacf (2 syringe) 40 mg/0.8mL Syringe - 0.11/day</li> <li>• Adalimumab-aacf (ps/uv starter) 40 mg/0.8mL Pen - 0.11/day</li> <li>• Adalimumab-aacf(CD/UC/HS) 40 mg/0.8mL Pen - 0.11/day</li> <li>• Adalimumab-adaz 40 mg/0.4mL Pen - 0.22/day</li> <li>• Adalimumab-adaz 40 mg/0.4mL Syringe - 0.22/day</li> <li>• Adalimumab-adbm (2 pen) 40 mg/0.4mL Pen - 0.22/day</li> <li>• Adalimumab-adbm (2 pen) 40 mg/0.8mL Pen - 0.22/day</li> <li>• Adalimumab-adbm (2 syringe) 10 mg/0.2mL Syringe - 0.08/day</li> <li>• Adalimumab-adbm (2 syringe) 20 mg/0.4mL Syringe - 0.08/day</li> <li>• Adalimumab-adbm (2 syringe) 40 mg/0.4mL Syringe - 0.22/day</li> <li>• Adalimumab-adbm (2 syringe) 40 mg/0.8mL Syringe - 0.11/day</li> <li>• Adalimumab-adbm(cd/uc/hs strt) 40 mg/0.4mL Pen - 0.22/day</li> <li>• Adalimumab-adbm(cd/uc/hs strt) 40 mg/0.8mL Pen - 0.22/day</li> <li>• Adalimumab-adbm(ps/uv starter) 40 mg/0.4mL Pen - 0.22/day</li> <li>• Adalimumab-adbm(ps/uv starter) 40 mg/0.8mL Pen - 0.22/day</li> <li>• Ajoyv (fremanezumab-vfrm) Autoinjector - 0.06/day</li> <li>• Ajoyv (fremanezumab-vfrm) Syringe - 0.06/day</li> <li>• Ingrezza 40 mg Sprinkle Capsule - 1/day</li> <li>• Ingrezza 60 mg Sprinkle Capsule - 1/day</li> <li>• Ingrezza 80 mg Sprinkle Capsule - 1/day</li> <li>• Skyrizi 150 mg Dose Kit - 0.04/day</li> <li>• Skyrizi 150 mg/mL Pen - 0.04/day</li> <li>• Skyrizi 150 mg/mL Syringe - 0.04/day</li> <li>• Skyrizi 180 mg/1.2 mL On-Body Injector - 0.03/day</li> <li>• Skyrizi 360 mg/2.4 mL On-Body Injector - 0.05/day</li> <li>• Tezspire (tezepelumab) Syringe - 0.07/day</li> </ul>	<p>The Committee approved as presented. The Quantity Limit Additions will be sent to PARP for approval.</p>	<p>F. Vaisberg</p>	<p>Resolved</p>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
	<ul style="list-style-type: none"> <li>• Tezspire Pen - 0.07/day</li> <li>• Tyenne 162 mg/0.9 mL Autoinjector - 0.13/day</li> <li>• Tyenne 162 mg/0.9 mL Syringe - 0.13/day</li> <li>• Xiidra Dropperette - 2/day</li> </ul>			
<b>III. Specialty Drug Additions</b>	<p>The Committee reviewed the Specialty Drug Additions. The Committee approved as presented.</p> <ul style="list-style-type: none"> <li>• Itovebi 3, 9mg tablets</li> <li>• Miplyffa 47, 62, 93, 124mg capsules</li> <li>• Scemblix 20, 40, 100mg tablets</li> <li>• Vyalev 240-12mg/mL injection</li> <li>• Dasatinib 20, 50, 70, 80, 100, 140 mg tablets</li> <li>• Ebglyss 25/2mL auto-injector</li> <li>• Tyenne 162mg/0.9mL auto-injector and syringe</li> <li>• Tremfya 100mg/mL pen-injector and syringe, 200mg/2mL auto-injector and syringe</li> <li>• Acthar 80unit/mL auto-injector</li> <li>• Livdelzi 10mg capsule</li> <li>• Lazcluze 80, 240mg tablet</li> <li>• Nemluvio 30mg auto-injector</li> <li>• Taltz 20mg/0.25mL, 40mg/0.5mL</li> <li>• Torpenz 2.5, 5, 7.5, 10mg tablet</li> <li>• Trikafta 59.5, 75mg pak</li> <li>• Voranigo 10, 40mg tablet</li> <li>• Zejula 200, 300mg tablet</li> </ul>	<p>The Committee approved as presented. The Specialty Drug Additions will be sent to PARP for approval.</p>	<p>F. Vaisberg</p>	<p>Resolved</p>
<b>IV. New Drug Review</b>	<p>R. John presented the New Drug Review list to the Committee. The following new products were reviewed and will be kept as non-formulary:</p> <ul style="list-style-type: none"> <li>• Vyloy (zolbetuximab-clzb) Injection</li> <li>• Vyalev (foscarbidopa and foslevodopa) Injection - formerly ABBV-951</li> <li>• Hympavzi (marstacimab-hncq) Injection</li> <li>• Itovebi (inavolisib) Tablets</li> <li>• Imuldosa (ustekinumab-srlf) Injection</li> <li>• Flyrcado (flurpiridaz F 18) Injection</li> <li>• Otulfi (ustekinumab-aauz) Injection</li> <li>• Cobenfy (xanomeline and trospium chloride) Capsules</li> <li>• Aqneursa (levacetylleucine) Granules for Oral Suspension</li> <li>• Miplyffa (arimoclomol) Capsules</li> <li>• Ebglyss (lebrikizumab-lbkz) Injection</li> <li>• Ocrevus Zunovo (ocrelizumab &amp; hyaluronidase-ocsq) Injection</li> </ul>	<p>The Committee approved the New Drug Review as presented and recommended.</p>	<p>R. John</p>	<p>Resolved</p>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
	<ul style="list-style-type: none"> <li>• <i>Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) Injection</i></li> <li>• <i>Boruzu (bortezomib) Injection</i></li> <li>• <i>Pavblu (aflibercept-ayyh) Injection</i></li> <li>• <i>Lazcluze (lazertinib) Tablets</i></li> <li>• <i>Niktimvo (axatilimab-csfr) Injection</i></li> <li>• <i>Livdelzi (seladelpar) Capsules</i></li> </ul>			

**V. Adjournment**

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held February 2025.



12/17/2024

\_\_\_\_\_  
Danielle Dolores, Director of Pharmacy Services

\_\_\_\_\_  
Date